文献速递妇科

LIBERTY随机撤药研究:relugolix复方疗法治疗子宫肌瘤相关月经过多

LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids.
PubMed 文献 · Am J Obstet Gynecol · 2023-09-02

LIBERTY随机撤药研究纳入完成LIBERTY 1/2及长期扩展研究且达应答标准的子宫肌瘤相关月经过多女性,随机接受relugolix复方疗法或安慰剂治疗52周。至第76周,relugolix组78.4%维持月经失血量<80 mL,安慰剂组15.1%(差值63.4%,95%CI 52.9%-73.9%,P<.0001)。

要点

  • 至第76周,relugolix组78.4%维持月经失血量<80 mL,安慰剂组15.1%(P<.0001)。
  • 至第104周,relugolix组69.8%维持月经失血量<80 mL,安慰剂组11.8%(P<.0001)。
  • relugolix复方疗法总体耐受良好,第2年不良事件谱与第1年一致,骨密度一般得以保持。

核心结论

  • 治疗2年后,relugolix复方疗法在维持子宫肌瘤相关月经过多女性低月经失血量方面显示疗效持久性。
  • 多数女性停药后月经过多及相关症状复发,再次接受relugolix复方疗法后改善。
  • relugolix复方疗法耐受良好,不良事件谱保持一致,平均骨密度在2年治疗期间一般得以保持。

研究设计与样本

  • 3期LIBERTY随机撤药研究:完成24周LIBERTY 1或2研究及28周长期扩展研究(总治疗至52周)且达应答标准(第48周月经失血量<80 mL且较关键研究基线减少≥50%)的女性,按1:1随机接受盲法relugolix复方疗法(relugolix 40 mg、雌二醇1 mg、醋酸炔诺酮0.5 mg,每日一次)或安慰剂治疗52周(总治疗期104周)。
  • 研究期间月经过多复发(月经失血量≥80 mL)的女性接受开放标签relugolix复方疗法。
  • 主要终点为至第76周(随机撤药研究第24周)维持月经失血量<80 mL的女性比例。
  • 分析基于改良意向治疗人群,包括所有接受≥1剂研究药物的随机女性。
  • 共229例女性随机(relugolix复方疗法n=115,安慰剂n=114),228例接受研究药物,175例(76.7%)完成随机撤药研究。

主要发现

  • 至第76周,relugolix组78.4%维持月经失血量<80 mL vs 安慰剂组15.1%(差值63.4%,95%CI 52.9%-73.9%,P<.0001)。
  • 至第104周,relugolix组69.8%维持月经失血量<80 mL vs 安慰剂组11.8%(差值58.0%,95%CI 47.0%-69.1%,P<.0001)。
  • 至第104周,安慰剂组88.3%月经过多复发(中位复发时间5.9周)。
  • 安慰剂组89例复发并接受开放标签补救治疗的女性中,87例对relugolix复方疗法应答,月经失血量<80 mL。
  • 第76周达到或维持闭经的比例:relugolix组57.4% vs 安慰剂组13.3%(差值44.1%,95%CI 33.10%-55.1%,P<.0001);第104周:relugolix组58.3% vs 安慰剂组10.6%(差值47.6%,95%CI 37.0%-58.3%,名义P<.0001)。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: In the pivotal LIBERTY 1 and 2 trials and long-term extension study, once-daily relugolix combination therapy (40 mg relugolix, 1 mg estradiol, 0.5 mg norethindrone acetate) reduced menstrual blood loss volume and pain among women with uterine fibroids. Relugolix combination therapy was well tolerated with preservation of bone mineral density through 52 weeks. OBJECTIVE: This study aimed to report the 2-year relugolix combination therapy efficacy and safety results of the phase 3 LIBERTY randomized withdrawal study. STUDY DESIGN: Women with uterine fibroid-associated heavy menstrual bleeding who completed the 24-week LIBERTY 1 or 2 trials, followed by the 28-week long-term extension study (up to 52 weeks total treatment), and who met the responder criteria (menstrual blood loss volume <80 mL and ≥50% reduction from pivotal study baseline at week 48 [week 24 of long-term extension]) were randomized in a 1:1 ratio to either blinded treatment with relugolix combination therapy or placebo for 52 weeks (total treatment period, 104 weeks). For women who had a relapse of heavy menstrual bleeding during the study (menstrual blood loss volume ≥80 mL), open-label relugolix combination therapy was offered. The primary endpoint was the proportion of women who maintained menstrual blood loss volume <80 mL through week 76 (week 24 of randomized withdrawal study). Secondary endpoints included time to menstrual blood loss volume ≥80 mL, proportion of women who maintained a menstrual blood loss volume of <80 mL through week 104 (over the 52-week randomized treatment period), the proportion of women who achieved or maintained amenorrhea at week 76 at the end of treatment, and the change in Uterine Fibroid Symptom-Quality of Life Bleeding and Pelvic Discomfort Scale and symptom severity scores. Analyses were performed for the modified intent-to-treat population, including all randomized women who received ≥1 dose of the study drug. RESULTS: Of the 229 randomized women (relugolix combination therapy, n=115; placebo, n=114), 228 received the study drug and 175 (76.7%) completed the randomized withdrawal study. Through week 76, 78.4% of women on relugolix combination therapy maintained menstrual blood loss volume <80 mL vs 15.1% in the placebo group (difference, 63.4%; 95% confidence interval, 52.9%-73.9%; P<.0001). At week 104, 69.8% of women on relugolix combination therapy maintained menstrual blood loss volume <80 mL vs 11.8% in the placebo group (difference, 58.0%; 95% confidence interval, 47.0%-69.1%; P<.0001). Through week 104, 88.3% of women on placebo relapsed with heavy menstrual bleeding (median time to relapse, 5.9 weeks). Among the 89 women in the placebo group who relapsed and received open-label rescue treatment, 87 women responded to relugolix combination therapy with a menstrual blood loss volume <80 mL. The proportion of women who achieved or maintained amenorrhea were 57.4% vs 13.3% at week 76 (difference, 44.1%; 95% confidence interval, 33.10%-55.1%; P<.0001) and 58.3% vs 10.6% at week 104 (difference, 47.6%; 95% confidence interval, 37.0%-58.3%; nominal P<.0001) for relugolix combination therapy and the placebo group, respectively. Relugolix combination therapy was generally well tolerated; no new safety signals were identified, and the adverse event profile over the second year was consistent with that reported through the first year of treatment. Bone mineral density remained stable in women who received relugolix combination therapy from week 52 to week 104. In women continuously treated with relugolix combination therapy up to 2 years, bone mineral density was generally preserved. CONCLUSION: After 2 years of treatment with relugolix combination therapy, there was evidence of durability of the effect in maintaining low menstrual blood loss volume in women with symptomatic uterine fibroids. Most women had return of heavy menstrual bleeding and associated symptoms after treatment cessation, which improved upon retreatment with relugolix combination therapy. Relugolix combination therapy was well tolerated, the adverse event profile remained consistent, and the mean bone mineral density was generally preserved through 2 years of treatment.

来源:Am J Obstet Gynecol,查看原文。版权归原作者所有。

引用

  1. Al-Hendy A, Venturella R, Arjona Ferreira JC, et al. LIBERTY randomized withdrawal study: relugolix combination therapy for heavy menstrual bleeding associated with uterine fibroids. Am J Obstet Gynecol. 2023. PMID: 37666383. doi:10.1016/j.ajog.2023.08.030

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。